Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan

OBJECTIVE: Leuprorelin acetate (TAP-144-SR) is commonly used worldwide in prostate cancer patients. This study was conducted to assess the non-inferiority of a 6-month depot formulation of TAP-144-SR (TAP-144-SR [6M]) 22.5 mg to a 3-month depot formulation of TAP-144-SR (TAP-144-SR [3M]) 11.25 mg in...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuhiro, Namiki, Mikio, Fujimoto, Tsukasa, Takabayashi, Nobuyoshi, Kudou, Kentarou, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653047/
https://www.ncbi.nlm.nih.gov/pubmed/26486824
http://dx.doi.org/10.1093/jjco/hyv149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653047/
https://www.ncbi.nlm.nih.gov/pubmed/26486824
http://dx.doi.org/10.1093/jjco/hyv149

Ejemplares similares